The combination of the SIRT2 inhibitor AGK2 and elesclomol promotes cuproptosis in gastric cancer cells by enhancing the lactylation of METTL16 at lysine 229 and increasing FDX1 protein levels [179]. This evidence concerns the gene FDX1 and gastric cancer.